Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01164722
Other study ID # AMC-076
Secondary ID U01CA121947AMC-0
Status Completed
Phase Phase 3
First received
Last updated
Start date April 2011
Est. completion date July 2016

Study information

Verified date July 2020
Source AIDS Malignancy Consortium
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

RATIONALE: Infrared coagulator ablation may be effective in preventing the development of anal cancer in patients with anal neoplasia

PURPOSE: This randomized phase III trial is studying infrared coagulator ablation to see how well it works compared to observation in preventing anal cancer in HIV-positive patients with anal neoplasia.


Description:

OBJECTIVES:

Primary

- Evaluate the complete response rate at 3 months and 1 year in HIV-seropositive patients with high-grade anal intraepithelial neoplasia (HGAIN) treated with infrared coagulator (IRC) ablation versus observation.

Secondary

- Determine the tolerability and safety of IRC ablation versus observation in these patients.

- Compare the proportion of patients with HGAIN at 1 year.

- Evaluate the response and recurrence rates at 1 year of individual lesions in patients treated with this regimen vs observation.

- Determine the incidence of metachronous lesions in these patients.

- Compare the response and recurrence rates at 2 years of individual lesions in patients under observation who subsequently received IRC ablation with the response and recurrence rates at 1 year in patients initially treated with IRC.

OUTLINE: This is a multicenter study. Patients are stratified according to site. Patients are randomized to 1 of 2 arms.

- Arm I: Infrared coagulator (IRC) contact tip is placed in direct contact with lesion under high-resolution anoscopy (HRA) guidance for 1.5 seconds. IRC ablation is reapplied until the level of submucosal vessels are reached.

- One week after each IRC ablation, patients complete a questionnaire regarding pain, bleeding, and other complaints.

- Arm II: Patients receive standard of care and undergo observation. After 12 months, patients may receive IRC ablation to all anal intraepithelial neoplasia lesions.

NOTE: Patients may receive a maximum of 6 IRC treatments while on study (3 per year).

Patients undergo a physical exam, digital rectal exam, anal cytology, and HRA at baseline and periodically during study.

After completion of study therapy, patients are followed up periodically for 2 years.


Recruitment information / eligibility

Status Completed
Enrollment 120
Est. completion date July 2016
Est. primary completion date July 2015
Accepts healthy volunteers No
Gender All
Age group 27 Years and older
Eligibility DISEASE CHARACTERISTICS:

- Diagnosis of high-grade anal intraepithelial neoplasia (AIN) meeting the following:

- AIN2 and/or AIN3 confirmed by biopsy = 2 weeks to = 60 days before enrollment

- 1-3 lesions with each lesion = 15 mm in diameter

- At least one high-grade AIN lesion is still visible at study entry

- HIV-infection documented by federally approved, licensed HIV-test in conjunction with screening test (e.g., ELISA, western blot, or other test)

- HIV-infection, based on prior ELISA and western blot assays, recorded and documented by another physician, allowed provided patient undergoes an approved antibody test to confirm diagnosis

- Patients on concurrent anti-retroviral therapy with a history of HIV-positivity based on an approved antibody test allowed

- Detectable plasma HIV-1 RNA also allowed

- No perianal AIN, perianal condyloma, or lower vulvar intraepithelial neoplasia or condyloma requiring treatment

PATIENT CHARACTERISTICS:

- Karnofsky performance status 70-100%

- Life expectancy = 2 years

- CD4 count = 200/mm³

- ANC > 750/mm³

- Platelet count = 75,000/mm³

- Hemoglobin = 9.0 g/dL

- INR and aPTT normal

- Negative pregnancy test

- Fertile patients must use effective contraception

- Female patients must have undergone cervical pap smear (if having a cervix) and gynecologic evaluation within the past 12 months

- Must be capable of complying with the requirements of this protocol

- Concurrent HPV-related disease allowed

- No history of anal cancer

- No acute infection or other serious medical illness requiring treatment within the past 14 days

- Fungal infection of the skin or a sexually transmitted disease requiring treatment allowed

- No concurrent malignancy requiring systemic therapy

- Kaposi sarcoma limited to the skin allowed

PRIOR CONCURRENT THERAPY:

- No prior infrared coagulator (IRC) ablation for high-grade anal intraepithelial neoplasia (HGAIN)

- Prior HGAIN treated by any means other than IRC within the past 2 months allowed

- At least 5 days since prior coumadin or clopidogrel and = 7 days after study therapy before receiving coumadin or clopidogrel again

- No concurrent anticoagulant therapy other than aspirin or NSAIDs

- More than 3 months since prior and concurrent systemic corticosteroids, cytokines, or immunomodulatory therapy (e.g., interferons) or local imiquimod

- No concurrent systemic therapy

Study Design


Related Conditions & MeSH terms


Intervention

Other:
clinical observation
Patients undergo observation
Device:
infrared photocoagulation therapy
Anal infrared coagulator ablation

Locations

Country Name City State
United States Boston University Cancer Research Center Boston Massachusetts
United States UCLA Clinical AIDS Research and Education (CARE) Center Los Angeles California
United States Laser Surgery Care New York New York
United States New York Weill Cornell Cancer Center at Cornell University New York New York
United States University of Pittsburgh Medical Center Pittsburgh Pennsylvania
United States UCSF Helen Diller Family Comprehensive Cancer Center San Francisco California
United States Benaroya Research Institute at Virginia Mason Medical Center Seattle Washington

Sponsors (4)

Lead Sponsor Collaborator
AIDS Malignancy Consortium National Cancer Institute (NCI), The Emmes Company, LLC, University of Arkansas

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Complete Response Through 1 Year No detection of high grade anal intraepithelial neoplasia (HGAIN) from treatment through one year. Detection of HGAIN was based on local pathology reports. 1 year post treatment
Secondary Tolerability and Safety of Infrared Coagulator Ablation Number of patients who experienced a serious adverse events All study visits through year 2
Secondary Proportion of Patients With High-grade Anal Intraepithelial Neoplasia at 1 Year Number of patients who had high grade anal intraepithelial neoplasia at one year. 1 year on study
Secondary Recurrence Rate at 1 Year 1 year on study
Secondary Incidence of Metachronous Lesions Number of patients with one or more metachronous lesions one year on study
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT05060471 - PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced SCCA Patients Phase 2
Active, not recruiting NCT02135419 - Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions Phase 3
Completed NCT05518201 - Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old Phase 1
Withdrawn NCT02857608 - A Prospective, Open-Label, Multi-center Comparison of Lymphoseek Identified Lymph Nodes and Clinically Identified Lymph Nodes of Subjects With Known Cancer of the Anus Phase 2
Active, not recruiting NCT02546973 - Quality of Life in Patients With Anal Cancer
Terminated NCT00903396 - Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer Phase 2
Terminated NCT00896467 - Psychological and Emotional Impact in Patients Undergoing Treatment For Metastatic Cancer Either in a Clinical Trial or as Standard Off-Trial Therapy N/A
Completed NCT00550589 - Cidofovir in Treating HIV-Infected Patients With High-Grade Squamous Intraepithelial Lesions of the Skin Near the Anus Phase 2
Completed NCT00324415 - Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer Phase 2
Terminated NCT00568425 - QOL & Functional Outcomes After Combined Modality Tx for Anal CA: Comparison of Conventional vs IMRT
Terminated NCT00267787 - Molecular Genetic and Pathological Studies of Anal Tumors
Completed NCT00066430 - Infrared Coagulation in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia Phase 1
Completed NCT04083053 - High-Resolution Anoscopy Perceived Discomfort Study N/A
Completed NCT03506529 - Identification of Predictive Factors for Physiological Hypermetabolism of the Anal Canal in 18F-FDG PET / CT
Recruiting NCT05835947 - Anal Cancer Risk In Women
Not yet recruiting NCT03947775 - HPV-SAVE_Merck_Sub-Study for Preventing Recurrence of HSIL Phase 2
Recruiting NCT04857528 - Detecting HPV DNA in Anal and Cervical Cancers
Recruiting NCT04708470 - A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers Phase 1/Phase 2
Recruiting NCT04907643 - Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes N/A
Active, not recruiting NCT01937780 - Anal Cancer Radiotherapy Study